SparingVision, a Paris-based startup company with Pittsburgh ties and gene therapy treatments for eye problems, has raised about $50 million in its most recent financing round.
To date, the 2-year-old pre-clinical company has raised $70 million and the proceeds from the most recent funding round will be used to advance development of SparingVision’s gene therapy treatment for retinitis pigmentosa, one of the most common inherited retinal diseases that cause eventual blindness.
SparingVision, which employs 12 people, is a company that’s using 20 years of eye research by Jose-Alain Sahel, chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine. Dr. Sahel, co-founder of SparingVision with Thierry Leveillard, was recruited to Pitt in 2016.
Paris Eye Disease Company with Pittsburgh Ties Raises $50 Million
